The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: Questions Adults With Persistent Acne Can Ask a Dermatologist

The 2026 protocol pairs oral probiotics with a topical secretome for mild-to-moderate facial acne. Adults with persistent acne can ask a dermatologist whether this add-on approach fits their lesion pattern and current prescriptions.

Secretome means a cell-derived preparation applied to skin alongside standard medication in this trial. According to BMJ Open, the double-blind randomized trial was planned for June 2025 to June 2026 the trial protocol. Use your visit to compare possible fit, prescription overlap, and which outcome would show benefit for you.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

What the trial combination contains
Do you fit the acne definition used?
How does add-on care change daily treatment?
Which results should you ask about?
What limits and proven options frame the choice?

What the trial combination contains

The BMJ Open protocol uses oral HEXBIO granules with six probiotic strains. The protocol names Lactobacillus acidophilus BCMC 12130 and L. casei BCMC 12313 among them.

It also names Bifidobacterium bifidum BCMC 02290 and B. longum BCMC 02120. Participants also apply nightly clindamycin-tretinoin cream to acne areas. The BMJ Open protocol therefore tests added microbiome therapy, not probiotics or secretome alone.

Do you fit the acne definition used?

The protocol enrolls dermatologist-diagnosed facial acne using Lehmann lesion counts. The BMJ Open protocol sets clear cutoffs for mild and moderate disease.

Ask your dermatologist to map your current comedones, papules, and pustules to these bands. Bring notes on flare timing, prior prescriptions, and areas affected. That count decides whether the trial definition resembles your acne.

mild: fewer than 20 comedones or 15 papules or pustules
moderate: up to 100 comedones or 50 papules or pustules

How does add-on care change daily treatment?

Nightly clindamycin-tretinoin targets inflammation and supports skin renewal in the trial. Added probiotics and secretome do not replace that base cream.

Ask whether to continue your current retinoid, antibiotic, or combination product during such a regimen. Ask how to apply the cream, where to avoid, and what irritation to report. Ask what to pause before starting and how long to wait for response.

Which results should you ask about?

The protocol measures gut and skin microbiome sequencing. It also tracks blood IL-6 and tryptophan metabolites.

Clinical skin measures record visible change. Ask which endpoint best reflects your goal: fewer lesions, lower inflammation signals, or microbial shifts. Ask how your dermatologist would judge benefit without full laboratory testing.

What limits and proven options frame the choice?

The authors state the key limitation is a small sample of 64 patients. That size may miss smaller effects across outcomes. The American Academy of Dermatology's 2024 acne guidance strongly recommends benzoyl peroxide, topical retinoids, antibiotic combinations, and oral isotretinoin for severe acne current acne guidance.

Ask how those proven options compare for your severity and history. No exosome or MSC-secretome product has FDA or EMA approval for dermatologic use, according to 2026 dermatology reporting mythbuster on exosomes in skin care. According to a 2026 PMC narrative review, US cell-derived exosome treatment products require trial oversight as unapproved drugs or biologics exosome regulation review. Ask whether any local secretome offer operates under formal trial oversight.